6857-34-7

Usage

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 4010221 is used as a central nervous system depressant for the treatment of anxiety disorders and insomnia. It helps in reducing anxiety and inducing sleep by depressing the central nervous system.
CHEMBRDG-BB 4010221 is used as a muscle relaxant for treating conditions such as muscle spasms and convulsions, due to its ability to relax muscles and reduce involuntary muscle contractions.

InChI:InChI=1/C9H8N2S/c12-9-10-6-8(11-9)7-4-2-1-3-5-7/h1-6H,(H2,10,11,12)

Upstream product

• 6097-58-1 ethyl 2-phenyl-2-aminoacetate 
• 333-20-0 potassium thioacyanate 
• 613-89-8 2-Aminoacetophenone 
• 5468-37-1 2-aminoacetophenone hydrochloride 
• 98-86-2 acetophenone 
• 70-11-1 α-bromoacetophenone 
• 64220-19-5 2-mercapto-4-phenylimidazole-5-carboxylic acid 
• 37394-52-8 hexamethylene tetramine salt of ω-bromoacetophenone 
• 64220-13-9 methyl 2-mercapto-4-phenylimidazole-5-carboxylate 
• 38061-18-6 methyl 5-phenyl-4-oxazolecarboxylate 
• 38061-23-3 α-Phenylacyl amino acid methyl ester hydrochloride 

Downstream Products

• 301857-39-6 2-butylmercapto-4-phenyl-1⁽³⁾H-imidazole 
• 6297-94-5 2-benzylsulfanyl-4-phenyl-1⁽³⁾H-imidazole 
• 132346-59-9 2-(4-chloro-benzylmercapto)-4-phenyl-1⁽³⁾H-imidazole 
• 67642-99-3 4-phenyl-2-propylsulfanyl-1⁽³⁾H-imidazole 
• 108952-86-9 (4-phenyl-1⁽³⁾H-imidazol-2-ylmercapto)-acetone 
• 25968-20-1 3-methyl-6-phenylimidazo[2,1-b]-thiazole 
• 109508-79-4 3-(4-phenyl-1⁽³⁾H-imidazol-2-ylmercapto)-pentane-2,4-dione 
• 133493-38-6 1-phenyl-2-(4-phenyl-1⁽³⁾H-imidazol-2-ylmercapto)-ethanone 
• 99984-40-4 6-phenyl-2,3-dihydro-imidazo[2,1-b]thiazol-3-ol 
• 7008-63-1 6-phenylimidazo[2,1-b]thiazole 
• 107922-02-1 1-(3-methyl-6-phenylimidazo[2,1-b][1,3]thiazol-2-yl)ethanone 
• 99974-06-8 4-imidazo[2,1-b]thiazol-6-yl-benzenesulfonic acid 

Relevant academic research and scientific papers

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site

Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment. The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors. Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition. We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity. Guided by molecular modeling, we synthesized and studied the structure-activity relationship of 40 compounds against clinically relevant EGFR mutants. We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line. We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.

TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR

The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.

NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS

This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective, amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

Method of making imidazole-2-thiones

The present invention provides a method of making an imidazole-2-thione which comprises the steps of reacting a vicinal diamine with a compound having a thiocarbonyl moiety and oxidizing the resulting reaction product to obtain said imidazole-2-thione.

Inhibitors of apoptosis in lymphocytes: Synthesis and biological evaluation of compounds related to pifithrin-α

The chemoprotection of cells from apoptosis induced by toxins or ionizing radiation could be important for biodefense and in the treatment of acute injuries. We describe a series of small heterocycles, including fused benzothiazoles, benzimidazoles, and related compounds, that abrogate thymocyte apoptosis induced by dexamethasone and γ-irradiation. To optimize the protective activity of the previously reported pifithrin-α (PFT-α, 1), various derivatives and analogues of this and the corresponding ring-closed imidazobenzothiazole (IBT, 39) were synthesized. The aromatic analogues of 39 were more protective than 39, while the aromatic analogues of 1 were not active. Compound 19 containing a pyrrolidinyl substituent on the phenyl ring provided potent antiapoptotic activity (EC50 of 1.31 μM compared to 4.16 μM for 1). Modification of aromatic 39 with a pyrrolidinyl para substituent (compound 60) enhanced the activity, lowering the EC50 to 0.35 μM. Also, 60 provided significant protection against γ-irradiation-induced apoptosis, as expected. Compounds 19 and 60 may be promising for potential clinical development.

Ambidentate properties of asymmetric substituted imidazoles. Direction of benzylation of 2-[N-(4-chlorophenyl)carbamoyl]methylthio-4-phenyl-1H-imidazole

On the basis of 1H-1H two dimensional NMR spectroscopy (NOESY) it has been unambiguously shown that the benzylation of 2-[N-(4-chlorophenyl)carbamoyl]methylthio-4-phenyl-1H-imidazole occurs at the N(1) atom. This data was